Oxford University Launches First Human Trial of Bundibugyo Ebola Vaccine Press Release

In July 2026, Oxford University launched the first human clinical trial of a vaccine targeting the Bundibugyo strain of the Ebola virus, marking a significant step towards strengthening global preparedness against one of the deadliest virus. It has launched the first human clinical trial of a vaccine targeting the Bundibugyo strain of the Ebola virus, marking a significant step towards strengthening global preparedness against one of the deadliest viral diseases. The early-stage study will assess the safety and immune response of the experimental vaccine in healthy adult volunteers.

The Phase I trial, named BD-Ebov, will effectively evaluate the ChAdOx1 BDBV vaccine in 50 healthy adults aged 18–55 years in Oxford. Researchers will examine the vaccine’s safety profile and its ability to generate an immune response against the Bundibugyo ebolavirus (BDBV), a less common but highly lethal species of the Ebola virus. The vaccine is based on Oxford’s ChAdOx1 viral vector platform, the same technology that was successfully used in developing the Oxford-AstraZeneca COVID-19 vaccine. Scientists believe the platform could accelerate the development of effective vaccines against emerging infectious diseases, including Ebola.

Although outbreaks caused by the Bundibugyo strain are relatively rare, the virus has been responsible for several deadly outbreaks in Africa, with reported case fatality rates of around 25-50%, according to the World Health Organization (WHO). Currently, approved Ebola vaccines primarily target the Zaire ebolavirus, leaving limited protection against other Ebola species.

Researchers state that the trial is part of broader global efforts to develop vaccines against multiple Ebola strains to strengthen outbreak preparedness. If the vaccine demonstrates favourable safety and immune responses, it could progress to larger clinical trials in regions at risk of Ebola transmission.

Healthcare experts have welcomed the initiative, noting that expanding the pipeline of strain-specific Ebola vaccines is essential for improving global health security. They said the trial represents an important milestone in pandemic preparedness and could help strengthen future responses to emerging viral outbreaks.

Impact on the Healthcare Market

Vaccines have been credited as the most effective tool in preventing and managing infectious diseases. They have drastically reduced the global disease burden, and a significant amount of progress has been made in understanding the nuances of the immune system and developing novel vaccine design and delivery platforms. From developing mRNA vaccines that offer rapid response to identifying novel antigenic targets for broader protection, the global healthcare landscape has been at the forefront of innovation.

Vaccinations can also help to reduce the fiscal burden by avoiding diseases, minimizing lost workdays and absenteeism, lowering disability claims, and increasing workforce productivity. The costs of non-vaccination represent a relevant issue. Vaccination also plays a key role in addressing the global challenge of antimicrobial resistance. Apart from quantifiable economic parameters, vaccines also have intangible benefits, reducing pain and avoiding quality of life lost and deaths.

Impact on the Vaccine Technologies Market

The global vaccine technologies market size was calculated at USD 55.01 billion in 2025 and is predicted to increase from USD 58.57 billion in 2026 to approximately USD 102.88 billion by 2035, expanding at a CAGR of 6.46% from 2026 to 2035.

According to Precedence Research, the market is driven by innovations such as mRNA and nanoball platforms, improving pandemic preparedness, production speed, and logistical reliability. It also reduces global mortality by managing infectious diseases, addressing chronic health issues, and supporting economic development through stable public health.

Genetic-based vaccines, such as mRNA and DNA, are a major driver due to their rapid development, allowing quick adaptation to new pathogens like SARS-CoV-2. It enhances safety by avoiding live viruses, promoting strong immune responses, and facilitating scalable manufacturing. These vaccines are designed and produced in weeks instead of years, playing a crucial role in effective pandemic response. The advanced manufacturing process allows for rapid, high-volume production, especially with mRNA platforms. By utilizing these technologies, vaccines are derived with targeted immune responses against specific antigens in preventive and therapeutic vaccination.

Impact on the Infectious Disease Vaccines Market

The global infectious disease vaccines market size accounted for USD 38.83 billion in 2025 and is predicted to increase from USD 41.60 billion in 2026 to approximately USD 77.04 billion by 2035, expanding at a CAGR of 7.09% from 2026 to 2035.

According to Precedence Research, the increased prevalence of infectious diseases and advancements in vaccine technology are driving the global market. The government initiatives and support are further contributing to the market growth. The market is further fueled by the requirement for new trial designs and technology solutions to improve the speed and flexibility of infectious disease vaccine research and development. The government emphasizes preventing potential future risk of infectious diseases, and is contributing to rising investments in R&D and immunization programs.

The growing emphasis on vaccine technology advances, such as mRNA, viral vector, and recombinant protein technologies, is enhancing the development, scalability, and flexibility of vaccines. The ongoing rapid surge in development of novel and therapeutic vaccines by using existing vaccines for therapeutic uses is projected to expand the emerging market.